SCHEMBL17080888

SCHEMBL17080888

CS(=O)(=O)OCCCCCc1ccc2ccc(=O)[nH]c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR1A P08908 5/20 0.41
▸ DRD2 P14416 5/20 0.41
▸ HTR2A P28223 5/20 0.41
▸ SLC6A4 P31645 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ USP2 O75604 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ MMP9 P14780 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ POLB P06746 3/20 0.38
▸ ACHE P22303 1/20 0.38
▸ MAOB P27338 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.37
▸ TP53 P04637 1/20 0.36
▸ BACE1 P56817 1/20 0.36
▸ PDE3B Q13370 2/20 0.35
▸ PDE3A Q14432 2/20 0.35
▸ P2RY12 Q9H244 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17081010 0.99 HTR1A (0.41) HTR1ADRD2HTR2ASLC6A4KDM4E
SCHEMBL17081005 0.95 POLB (0.39) HTR1ADRD2HTR2ASLC6A4KDM4E
SCHEMBL18373350 0.89 ACHE (0.41) HTR1ADRD2HTR2ASLC6A4LMNA
SCHEMBL18496112 0.81 DRD2 (0.49) DRD2ACHEMAOB
SCHEMBL29923245 0.81 DRD2 (0.49) DRD2ACHEMAOB
SCHEMBL18932514 0.80 GPR84 (0.47) HTR1ADRD2HTR2ASLC6A4MAPT
SCHEMBL18932519 0.79 GPR84 (0.47) HTR1ADRD2HTR2ASLC6A4CA12
SCHEMBL18932524 0.77 GPR84 (0.47) HTR1ADRD2HTR2ALMNATSHR
SCHEMBL28100544 0.77 TP53 (0.37) DRD2KDM4EALDH1A1LMNAMMP9
SCHEMBL18944234 0.76 PDE3B (0.49) HTR1ADRD2HTR2ASLC6A4BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3115361-B1 HETEROCYCLIC COMPOUNDS, AND PREPARATION METHOD AND USE THEREOF SHANGHAI INST MATERIA MEDICA CAS (CN) 2019-10-23 — — EP disclosed
US-10174011-B2 Heterocyclic compounds, process for preparation of the same and use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2019-01-08 — — US disclosed
US-20170158680-A1 HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2017-06-08 — — US disclosed
US-20170158680-A1 HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2017-06-08 — — US disclosed
EP-3115361-A1 HETEROCYCLIC COMPOUNDS, AND PREPARATION METHOD AND USE THEREOF Shanghai Institute Of Materia Medica Chinese Academy of Sciences (CN) 2017-01-11 — — EP disclosed
EP-3115361-A1 HETEROCYCLIC COMPOUNDS, AND PREPARATION METHOD AND USE THEREOF Shanghai Institute Of Materia Medica Chinese Academy of Sciences (CN) 2017-01-11 — — EP disclosed
WO-2015131856-A1 HETEROCYCLIC COMPOUNDS, AND PREPARATION METHOD AND USE THEREOF 中国科学院上海药物研究所 2015-09-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10174011-B2 Heterocyclic compounds, process for preparation of the same and use thereof CYP11B2, CYP11B1, ADCYAP1R1 HTR1A 1013/4885DRD2 1826/4885HTR2A 1202/4885
US-20170158680-A1 HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF CYP11B2, CYP11B1, ADCYAP1R1 HTR1A 1013/4885DRD2 1826/4885HTR2A 1202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback